Breast cancer

Summary

The Breast Cancer research group aims to better understand breast cancer development, the origin of disease subtypes, and disease progression and vulnerabilities. The research projects comprise the major disease subtypes as well as BRCA1/2-mutant breast cancer. The group also works to develop novel targeted preventive approaches and to improve the quality of life of patients. This is a multidisciplinary team that combines the experience and knowledge of clinical and translational researchers.

320 Publications

Strategic lines

Selected Publications

- Pernas S, Villagrasa P, Vivancos A, Scaltriti M, Rodón J, Burgués O, Nuciforo P, Canes J, Paré L, Dueñas M, Vidal M, Cejalvo JM, Perelló A, Llommbard Cussac A, Dorca J, Montaño A, Pascual T, Oliveira M, Ribas G, Rapado I, Prat A, Ciruelos E. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front. Oncol. 2021;11744112-744112. doi:10.3389/fonc.2021.744112. IF:6,24.

- Sun X, Wu B, Chiang HC, Deng H, Zhang X, Xiong W, Liu J, Rozeboom AM, Harris BT, Blommaert E, Gomez A, Garcia RE, Zhou Y, Mitra P, Prevost M, Zhang D, Banik D, Isaacs C, Berry D, Lai C, Chaldekas K, Latham PS, Brantner CA, Popratiloff A, Jin VX, Zhang N, Hu Y, Pujana MA, Curiel TJ, An Z, Li R. Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion. Nature. 2021;599(7886):673-678. doi:10.1038/s41586-021-04057-2. IF:49,96.

- Mahendralingam MJ, Kim H, McCloskey CW, Aliar K, Casey AE, Tharmapalan P, Pellacani D, Ignatchenko V, Garcia Valero M, Palomero L, Sinha A, Cruickshank J, Shetty R, Vellanki RN, Koritzinsky M, Stambolic V, Alam M, Schimmer AD, Berman HK, Eaves CJ, Pujana MA, Kislinger T, Khokha R. Mammary epithelial cells have lineage-rooted metabolic identities. Nat Metab. 2021;3(5):665-681. doi:10.1038/s42255-021-00388-6. IF:13,51.

- Liu Q, Palomero L, Moore J, Guix I, Espin R, Aytes A, Mao JH, Paulovich AG, Whiteaker JR, Ivey RG, Iliakis G, Luo DX, Chalmers AJ, Murnane J, Pujana MA, Barcellos Hoff MH. Loss of TGF beta signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Sci Transl Med. 2021;13(580):doi:10.1126/scitranslmed.abc4465. IF:17,96.

- Herranz C, Mateo F, Baiges A, de Garibay GR, Junza A, Johnson SR, Miller S, Garcia N, Capellades J, Gomez A, Vidal A, Palomero L, Espin R, Extremera AI, Blommaert E, Revilla Lopez E, Saez B, Gomez Olles S, Ancochea J, Valenzuela C, Alonso T, Ussetti P, Laporta R, Xaubet A, Rodriguez Portal JA, Montes Worboys A, Machahua C, Bordas J, Menendez JA, Cruzado JM, Guiteras R, Bontoux C, La Motta C, Noguera Castells A, Mancino M, Lastra E, Rigo Bonnin R, Perales JC, Vinals F, Lahiguera A, Zhang XH, Cuadras D, van Moorsel CHM, van der Vis JJ, Quanjel MJR, Filippakis H, Hakem R, Gorrini C, Ferrer M, Ugun Klusek A, Billett E, Radzikowska E, Casanova A, Molina M, Roman A, Yanes O, Pujana MA. Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis.

Selected Projects

- 19FIS022. Atlas de moduladores moleculares del cáncer y validación en el subtipo receptor estrógenopositivo de cáncer de mama. (PI18/01029). 2019-2022. IP:PUJANA GENESTAR,MIGUEL ANGEL.

- 21MAR010. Towards improving clinical management and care of lymphangioleiomyomatosis: integrative study of biomarkers and therapies (IMPROVE). (202029-30). FUNDACIO IDIBELL; FUNDACIÓ INSTITUT DE RECERCA VALL D’HEBRON; FUNDACIÓ LA MARATÓ DE TV3; INST. D'INVES.SAN. PERE VIRGILI; NATIONAL INSTITUTE OF TUBERCULOSIS AND LUNG DISEASES; THE UNIVERSITY OF NOTTINGHAM (UON). 2021-2024. IP:PUJANA GENESTAR,MIGUEL ANGEL.

- 21DPS006. Subvencions per a la formació de científics i tecnòlegs: modalitat personal investigador en formació (PIF-Salut). (SLT017/20/000076). DIR.GEN.SALUT PUBLICA, DEP.SALUT GE. 2021-2024. IP:PUJANA GENESTAR,MIGUEL ANGEL.

- 17FIS008. Evaluación de la reserva ovárica tras el tratamiento de los endometriomas comparando esclerosis con alcohol frente a cirugía. Impacto sobre la hormona antimulleriana (AMH). 2017-2021. IP:GARCIA TEJEDOR,AMPARO.

- 21FIS003. Perfil transcriptómico precoz durante el tratamiento como marcador predictivo de respuesta en Cáncer de Mama HER2-positivo. (PI20/00544). ISCIII. 2021-2023. IP:PERNAS SIMON,SONIA.

More Information

The group has extensive experience in bioinformatic and systems biology approaches, combined with in vitro and in vivo experimental studies, aimed at better understanding the development and progression of breast cancer. Over the past five years, the team has published 50 articles on a regular basis, including various manuscripts in leading journals. The team has also received various national and international grants and has established strong collaborations with national and international leaders in the area.